Owkin is entering a new partnership with AstraZeneca to develop a gBRCA pre-screening solution in breast cancer directly from digitised pathology slides
David Dellamonica shared a post by Chief Commercial Officer at Owkin,
“Incredibly proud of this strategic partnership.
Huge congratulations to Thomas Di Maio and all the team involved in this new venture !”
Quoting Jean-Frederic Petit-Nivard:
“Exciting News!
Owkin is delighted to enter into a new partnership with AstraZeneca to develop a gBRCA pre-screening solution, an AI-powered tool to pre-screen for gBRCA mutations (gBRCAm) in breast cancer directly from digitised pathology slides.
The goal of the collaboration is to develop accessible and robust diagnostic solutions to help patients get optimal care.”
Source: David Dellamonica/LinkedIn and
David Dellamonica is the Global Head of Precision Digital Healthcare at AstraZeneca. He leads the Precision Digital Health Delivery team, driving initiatives across all AstraZeneca business units and implementing digital solutions throughout the care pathway. He has authored publications on AI, oncology, cardio-metabolic care pathways, and value-based partnerships. Dellamonica also actively contributes to discussions on the European Commission’s Data Strategy and AI White Paper.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023